3Nahrendorf M, Hu K, Fraccarollo D, et al. Time course of right ventricular remodelling in rats with experimental myocardial infarction. Am J Physiol Heart Circ Physiol,2003, 284:H241-H248.
4Willenheimer R. Left ventrivular remodelling and dysfunction. Can the process be prevented? Int J Cardiol, 2000, 72,143-150.
5Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and rennin-angiotensin-aldosterone system. Circulation, 1991,83: 1849-1865.
6Kaikita K, Hayasaki T, Okuma T, et al. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol, 2004, 165: 439 - 447.
7Bolognese L,Carrabba N,Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation, 2004,109: 1121 - 1126.
8Nguyen Q, Colombo F, Clement R, et al. AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post -MI. Br J Pharmacol,2003, 138:1485-1494.
9Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on mortality and morbidity in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med,1999,341: 709-717.
10Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker , in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med,2003,348: 1309-1321.
